Neoadjuvant therapy for breast cancer: Evolution of practical guidelines

Pacific Medical Journal 2026 Open access

Read full text
Authors: Oksana Korshunova, Апанасевич Владимир Иосифович, E. V. Eliseeva, O. A. Argishev, Kirill V. Stegniy, Yu. Yu. Petukhova, О. М. Загрудинова
DOI: 10.34215/1609-1175-2025-4-11-15
Cited by: 0
References: 17

Abstract

The article provides an analytical review of neoadjuvant therapy for breast cancer, observing a paradigm shift in treatment over the past decade. This shift is due to emerging knowledge about the nature of the disease and opportunities to achieve better treatment outcomes. During the period under review, neoadjuvant therapy for breast cancer has evolved from standard regimens to dose-dense regimens, and to dual blockade (trastuzumab/pertuzumab) in the treatment of HER2-positive tumors.

Fields of Study & Subjects

Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Breast Lesions and Carcinomas

Publication details

Journal / source
Pacific Medical Journal
Issue
4
Pages
11–15
Publication date
15 February 2026
Language
EN